Drugs / RH5.1
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05385471 | Jan 2023 → Mar 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06958198 | Sep 2025 → Oct 2026 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 1 | NCT06141057 | Jun 2023 → Jul 2025 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04318002 | Jan 2021 → Aug 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05790889 | Apr 2023 → May 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Recruiting | Mixed |
| Phase 21 trial | ||||||
| Phase 2 | NCT07183371 | Dec 2025 → Dec 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT05978037 Comparator | Aug 2023 → Apr 2026 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT02927145 Comparator | Oct 2016 → Jun 2019 | malaria | University of Oxford | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | ExpreS2ion Biotechnologies | Results ExpreS2ion Biotech highlights BIO-002 clinical data supporting platform validation, scalability and partnered development model expres2ionbio.com ↗
Importantly, BIO-002 shows that a standard-dose regimen achieves similar immune responses to a higher-dose approach. |
| 2024-12-11 | ExpreS2ion Biotechnologies | Results Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine expres2ionbio.com ↗
These are the first data demonstrating the safety and efficacy of the RH5.1/Matrix-M blood-stage malaria vaccine in preventing clinical malaria over a six-month follow-up period in infants aged 5-17 months. |
| 2024-06-21 | ExpreS2ion Biotechnologies | Results Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine expres2ionbio.com ↗
These are the first data on the RH5.1/Matrix-M blood-stage malaria vaccine’s safety and immunogenicity in Tanzania published in the Lancet. |
| 2021-04-21 | ExpreS2ion Biotechnologies | Results Publication of clinical Phase I/IIa data in the RH5 blood-stage malaria vaccine expres2ionbio.com ↗
Minassian et al. report that the RH5.1/AS01B vaccine against blood-stage Plasmodium falciparum malaria is safe and immunogenic in the phase I/IIa clinical trial. |
| 2018-10-31 | ExpreS2ion Biotechnologies | Results ExpreS2ion meddelar positiva resultat från fas I/IIa-studie med malariavaccin av The Jenner Institute, Oxfords Universitet expres2ionbio.com ↗
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) meddelar idag att The Jenner Institute vid Oxfords Universitet i dag presenterar positiva resultat från sina kliniska fas I/IIa-studie med deras RH5.1-blodmalariavaccin vid ett vetenskapeligt möte i New Orleans. |
| 2018-10-31 | ExpreS2ion Biotechnologies | Results ExpreS2ion announces positive Phase I/IIa malaria vaccine trial results by The Jenner Institute, University of Oxford expres2ionbio.com ↗
Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that The Jenner Institute of the University of Oxford presents positive results from its Phase I/IIa clinical studies with their RH5.1 blood-stage malaria vaccine at a scientific meeting in New Orleans. |
| 2017-07-05 | ExpreS2ion Biotechnologies | Results Successful completion of Phase I and initiation of Phase IIa clinical trial of a universal malaria vaccine produced in ExpreS2 expres2ionbio.com ↗
The successfully completed part of the Phase I study assessed the safety of the vaccine and the immune response, as well as the optimal dosing regimen of the vaccine. |
| 2017-07-05 | ExpreS2ion Biotechnologies | Results Framgångsrikt färdigställande av klinisk fas I-studie och inledande av fas IIa-studie av universellt malariavaccin producerat i ExpreS2 expres2ionbio.com ↗ |
All press releases naming this drug 9 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RH5.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02927145 ↗ |
| Modality | Vaccine | “The RH5.1 recombinant protein vaccine, targeting the P. falciparum reticulocyte-binding protein homolog 5 (RH5), formulated in AS01B adjuvant.” PMID 34223402 ↗ Jun 2021 |
| Route | Intramuscular | “administered intramuscularly in healthy adults, young children and infants in Tanzania” NCT04318002 ↗ |